Purpose Population-based newborn screening using T-cell receptor excision circles (TREC) identifies infants with severe T-lymphopenia, seen in severe combined immunodeficiencies (SCID), but also infants with the 22q11 deletion syndrome (22q11DS). Methods for analysis of kappa-deleting recombination excision circles (KREC) help identifying infants with B-lymphopenia. We aimed to evaluate the occurrence of abnormal TREC or KREC newborn screening results in 22q11DS patients and assessed the clinical relevance of abnormal screening reports.
Introduction
Severe combined immunodeficiency (SCID) is a life-threatening inborn disease of infants, characterized by severe T-lymphopenia or defective function of T-and B-lymphocytes [1] . Rapid recognition of affected infants is necessary in order to prevent devastating infections and to provide curable treatment. Early diagnosis based on clinical findings is difficult, as these infants often appear well at birth and are not identified by clinical examination [2] . Methods of population-based newborn screening using the T-cell receptor excision circles (TREC) assay have successfully been introduced in several US states in order to identify infants with severe T-lymphopenia due to SCID [3, 4] . The TREC screening programs also detect infants with severe T-lymphopenia associated with other conditions, such as the 22q11 deletion syndrome (22q11DS, DiGeorge syndrome, velo-cardio-facial syndrome) [3] [4] [5] . While the TREC assay is used to detect severe T-lymphopenia at birth, similar methods for analysis of kappa-deleting recombination excision circles (KREC) identify infants with severe Blymphopenia, e.g. seen in X-linked agammaglobulinemia [6] .
Previous studies based on flow cytometry have shown that the majority of patients with 22q11DS feature mild to moderately decreased T-lymphocyte counts. Less than 1.5 % of all 22q11DS patients exhibit a severe T-lymphopenia comparable to SCID (complete DiGeorge syndrome) [7] . The T-lymphopenia observed in 22q11DS is explained by the impaired development of the thymus, largely caused by reduced or absent expression of the T-box transcription factor (TBX1). Although up to 50 genes can be deleted in patients with 22q11DS, the haploinsufficiency of TBX1 is the main contributor to the aberrant development of the thymus, the heart and the parathyroid glands [8] .
In a previous study from Sweden, using a combined TREC and KREC-assay, a large proportion (30 %) of infants with 22q11DS presented with abnormal TREC copy numbers [9] . However, as the clinical relevance of these findings is unknown, we conducted a retrospective study that involved the largest cohort of patients with 22q11DS studied so far with a combined newborn screening assay of TREC and KREC.
Primarily, our study intended to investigate the frequency of abnormal TREC copy numbers at birth in a larger group of patients with 22q11DS. In addition, we aimed to investigate a potential correlation of abnormal TRECs, low T-lymphocyte counts, and a more severe clinical picture during the first year of life. Finally, we intended to evaluate if a novel second tier test, applying triplex real-time quantitative PCR (qPCR) performed on dried blood spot samples (DBSS) from stored Guthrie cards, could be used to detect the hemizygous deletions of the TBX1 gene in order to verify 22q11DS in these patients.
Methods
Subjects The following inclusion criteria were applied: (i) All patients with 22q11DS confirmed by fluorescence in situ hybridization (FISH) or multiplex ligation dependent probe amplification (MLPA). (ii) Referral to the Queen Silvia Children's Hospital in Gothenburg, Sweden. (iii) Age below 18 years at the time of inclusion. Parents or legal guardians were contacted and informed consent was obtained. In order not to miss out on serious cases, deceased patients with confirmed 22q11DS who would have been less than 18 years of age were also included.
Neonatal Dried Blood Spot Samples Original DBSS collected from patients with 22q11DS at 3-5 days after birth were retrieved from cold storage. In addition, DBSS from 750 prospectively screened newborns and stored DBSS from patients with SCID (IL2RG or RAG1 gene mutations) or agammaglobulinemia (BTK gene mutations) were used as reference controls for the TREC/KREC screening assay. As shown before, properly stored DBSS are generally eligible for analysis with the TREC/KREC assay [10] .
TREC/KREC Screening Assay DNA was extracted from DBSS and a triplex real-time qPCR for TRECs, KRECs and beta-actin (ACTB) was performed on a ViiA7 real-time PCR system (Applied Biosystems) as previously described [6] . The qPCR procedure was optimized with custom reagents provided by Affymetrix (Santa Clara, CA, USA). Amplification of ACTB was not used for normalization, but to assess the success of DNA extraction from the DBSS. Abnormal TREC/KREC screening results were defined as <8 TRECs/μL or <6 KRECs/μL of dried blood, based on cut-off values established in screening trials in Sweden and Germany that involved >10.000 newborn samples from a general population. Abnormal results for TREC copy numbers were confirmed by re-testing of a second punch from the original DBSS. The re-run rate indicates the fraction of cases where a second (follow-up) Guthrie card would have to be requested and is based on cohort data of >10.000 Swedish and German newborns.
TBX1 Analysis A second-tier triplex real-time qPCR reaction, using the original DNA eluates from the DBSS, was performed in order to assess markers located on chromosomes 19 (PTBP1 gene) and 22 (TBX1 gene). The real-time qPCR reactions were performed as previously described [11] . The PTBP1 gene on chromosome 19 was used as an internal standard within the assay, based on the assumption of two allelic copies of this gene. The relative expression of the TBX1 gene on chromosome 22 was then normalized to the endogenous reference on chromosome 19 [12] . Thus, patients with 22q11DS would be characterized by hemizygous deletions of the TBX1 gene region.
Assessment of Lymphocyte Counts and Clinical Findings
The available medical records of all included 22q11DS patients at the Queen Silvia Children's Hospital were reviewed. For each patient, data from the time-of-diagnosis was retrieved regarding absolute counts for T-lymphocyte subpopulations (CD3+, CD4+, CD8+) and B-lymphocytes (CD19+), determined by routine flow cytometry, and occurrence of congenital heart defects verified by ultrasound-echocardiography. Published reference values were applied to assess occurrence of T-and B-lymphopenia. T-lymphopenia and B-lymphopenia was defined as absolute cell counts below the 10th percentile in age matched healthy children [13] . Medical records from the first year of life were reviewed in each patient for the occurrence of hypocalcaemia and a history of significant viral and bacterial infections. We defined a significant bacterial infection during first year of life as a single episode of bacterial pneumonia, septicemia, meningitis or osteomyelitis. A significant viral infection during the first year of life was defined as a viral infection requiring hospital admission or more than six episodes of viral infections including respiratory tract infections and/or gastroenteritis. According to previous studies, immaturity of the immune system and blood sampling through intravenous catheters may cause abnormal TREC screening results in preterm neonates [3] [4] [5] 9] . To rule out false positive TREC based newborn screening results caused by prematurity, we collected data on gestational age. In order to investigate if abnormal TREC copy numbers at birth are associated with a more severe clinical phenotype in 22q11DS patients, the TREC cut-off used for the SCID prospective screening trials in Sweden and Germany (<8 TREC copies/μL) was applied to segregate the patients into two groups. These two groups were further compared regarding lymphocyte counts, occurrence of heart defects, hypocalcaemia and infections.
Ethical Considerations The study was approved by the Regional Ethical Review boards in Gothenburg and Stockholm and was performed in accordance with the declaration of Helsinki and its later amendments.
Statistical Analysis The Mann-Whitney U test was applied to compare TREC copy numbers in patients with 22q11DS with a control group of newborns. Fisher's exact test was used to compare between the two groups of patients with 22q11DS, concerning categorical variables such as presence of heart defects and hypocalcaemia. Multiple logistic regression was used to verify differences in lymphocyte subsets when corrected for age at lymphocyte test. Statistical significance was defined as a p value <0.05. SPSS software version 20.0 (IBM) was used for statistical analyses.
Results
Subjects Forty-eight (55 %) of the 88 eligible patients with 22q11DS born between 1993 and 2010 were included (33 girls, 15 boys). Three patients declined participation and 37 did not reply to the invitation. TREC/KREC Screening Assay There was a statistically significant general trend for lower number of TRECs for the 22q11DS patients when compared to the control group of prospectively screened newborns (p<0.001). Nine of 48 patients (19 %) showed TREC numbers below the cut-off (from here on referred to as patients with abnormal TREC copies). All patients had KREC copy numbers within the normal range (Fig 1) .
Lymphocyte Counts and Clinical Findings
In the whole group of 48 included patients, CD3+ T-lymphopenia was found in 32 (67 %) patients at the time-of-diagnosis (Fig 2) . For CD4+, CD8+ and CD19+ lymphocytes, cell counts below 10th percentile of age matched normal was present in 30 (63 %), 23 (48 %) and ten (21 %) patients respectively [13] . Low B-cells at the time-of-diagnosis was however not reflected by abnormal KREC copies at birth. Thirty-nine (81 %) patients had a heart defect and 36 of these patients had undergone cardiac surgery. During their first year of life, 19 (40 %) patients had hypocalcaemia, 21 (44 %) suffered from significant viral infections and ten (21 %) suffered from significant bacterial infections. Table I . The patients with abnormal TREC copies showed significantly lower CD8+ T-lymphocytes at the time-of-diagnosis. In addition, an increased proportion of the patients with abnormal TREC copies suffered from significant viral infections during the first year of life, as compared to those with normal TREC copies at birth. All of the patients with abnormal TREC copies had T-lymphopenia, defined as a CD3+ lymphocyte count below the 10th percentile of normal at the time-of-diagnosis, but only one was diagnosed with the complete DiGeorge syndrome. This patient had no T-lymphocytes and suffered from severe CMV infection and hypocalcaemia when diagnosed at 3.5 months of age. No heart defect was seen, apart from a right-sided aortic arch. This patient, who would have been identified by prospective TREC/KREC newborn screening, died at 5 months of age following thymic transplantation.
Comparison Between Patients with Abnormal and Normal TREC Copies at Birth T-lymphocyte counts and clinical findings for the two groups are presented in
The group of 22q11DS patients with abnormal TREC copies was similar to the remaining group of patients with respect to gender, gestational age, occurrence of heart defects and age at diagnosis. In the group of patients with abnormal TRECs, one infant was born prematurely after 35 weeks of gestation. This infant had T-lymphopenia (900 CD3+ cells/μL).
TBX1 Analysis
The normalized number of TBX1 gene copies expressed in the 22q11DS patients was distinctly lower than the number expressed in a control group of newborns (Fig 3) .
Discussion

Frequency of Abnormal TREC Copies in Infants with 22q11DS
In the present study, abnormal TREC counts were found in 19 % of the infants with 22q11DS. Considering the incidence of the 22q11DS in approximately one in 4,000 births, as found in Gothenburg, Sweden, our findings indicate that these patients will constitute a relevant proportion of the total number of abnormal TREC test results found in population-based screening [14] . By comparison, reports from California and Wisconsin suggest that about 5 % to 10 % of all expected 22q11DS patients were identified by populationbased TREC newborn screening [4, 5] . In the Californian report this was calculated from an estimated incidence of 22q11DS of one in 5,000 births, which complicates comparison with the present study [5, 15] . There is also considerable variability in diagnostic algorithms and TREC screening methods used. The TREC cut-off in the present study was characterized by a re-run rate (i.e. the need to recall a second dried blood spot card) of 0.05 %. If this cut-off would have been lowered to equal a re-run rate of 0.01 % as used in various US states, only about 8 % of infants with 22q11DS Open boxes represent patients with >8 TRECs/μL. Gray areas depict the 10th to 90th percentile range of CD3+ T-lymphocytes in healthy children, while dotted lines represent medians in this reference population [13] would have been identified by the TREC screening in the present study. This exemplifies the impact of different cut-off values for the outcome of the TREC screening assay.
Our results are confined to patients with a known 22q11DS and therefore they might not represent all infants with 22q11DS. However, the inclusion criteria in the present study were wide, considering that the patients were not only referred to our hospital because of infectious problems or immunological abnormalities, but rather for systematic evaluation by the 22q11DS expert team or because they were in need of heart surgery.
Relevance of Abnormal TREC Screening Results in Infants with 22q11DS
In the present study, the TREC assay correctly identified the only infant with the complete DiGeorge syndrome. This patient would have benefited from TREC screening, facilitating an earlier diagnosis and thymus transplantation before onset of CMV infection. Even though the remaining 22q11DS patients with abnormal TREC screening results found in our study were not in need of immune-restoring therapy, our findings show that they had T-lymphopenia and most of them suffered from severe and recurrent viral infections. This is in accordance with another study where an association was found between T-lymphopenia and recurrent viral infections in 22q11DS patients [16] . In agreement with our findings, a previous study showed that the decrease in CD8+ T-cell counts was most pronounced in the infants with 22q11DS [17] . It is likely that early recognition and immunological follow-up of these patients would be of benefit to avoid infectious exposure, vaccination with live agents and to enable precaution regarding transfusion of blood products. In some cases, prophylactic treatment with antibiotics and immunoglobulins would have been appropriate [18] .
In the whole cohort, the majority of the patients had Tlymphopenia (Fig 2) , although only 19 % had abnormal TREC copy numbers. The present study demonstrates a general reduction of TREC copy numbers in patients with 22q11DS, which in turn could be explained by the various degree of thymus hypoplasia.
There does not seem to be a clearly defined group of 22q11DS patients with abnormal TREC copy numbers, and therefore the number of 22q11DS patients found in population based screening will depend on the threshold or cut-off applied.
Relevance of Normal KREC Screening Results in Infants with 22q11DS Although 22q11DS has classically been considered a T-lymphocyte disorder, there are now a growing number of reports indicating that abnormalities of the humoral immune system can also be associated with the syndrome [19] [20] [21] . The finding of normal KRECs in all 22q11DS patients in this study supports previous studies stating that this is likely secondary to T-lymphopenia or defect T-lymphocyte function, rather than a disorder of the B-cells per se [19, 20] . However both qualitative and quantitative B cell deficits were found in patients with 22q11DS in a previous study [17] .
Potential Benefit of Early Diagnosis of 22q11DS Through Screening Programs for SCID TREC-based newborn screening programs do not only identify infants with life threatening Fig. 3 Relative expression of the chromosome 22q11 marker gene TBX1 in dried blood spot samples from children with 22q11 deletion syndrome and control group of newborns immunodeficiencies, but also infants with T-lymphopenia associated with other conditions, such as complications due to congenital malformations and syndromes. Once infants present with abnormal TREC copy numbers in the screening, it is important to confirm the underlying diagnosis, in order to provide appropriate medical care. Based on the present results, the TBX1 analysis might serve a purpose as a rapid and inexpensive second tier test to confirm 22q11DS in the setting of abnormal TREC screening results. Patients with 22q11DS have many medical and developmental problems [15, 18, 22] . Therefore, a timely and correct diagnosis of the syndrome favors these patients, as it allows for early interventions and follow-up by multidisciplinary teams. In order to assist clinicians in caring for these patients, published guidelines present the best practice recommendations available [18] .
Conclusions
The present study demonstrates that a high proportion of infants with 22q11DS were identified by TREC-based newborn screening. Even though only a minority of the infants with 22q11DS and abnormal TREC copies suffered from a SCID-like severe immunodeficiency, T-lymphopenia was present in all of these infants. Thus, physicians involved in the clinical follow-up of screening programs should be aware of, and identify, patients with this syndrome. In the setting of abnormal TREC screening results, rapid and inexpensive diagnosis of 22q11DS is feasible using a TBX1 assay.
